ORMP

+ Watchlist + Portfolio

Oramed Pharmaceuticals Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.79
52-Week Range: $2.06 – $5.19
Market Cap: $199.25M
P/E (TTM): 1.16
EPS (TTM): 4.13
Dividend Yield: 5.22%

Advanced Metrics

Price/Book: 0.62
PEG Ratio: —
Return on Equity: 74.24%
Return on Assets: -3.42%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.98
Debt/Equity: 0.00
Total Debt: $733.00K
Free Cash Flow: $2.51M
Revenue Growth: —
Earnings Growth: 493.50%
Enterprise Value: $149.37M

ORMP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.70M	$1.34M	$0.00	$2.00M
Cost of Revenue	—	—	$0.00	$1.99M
Gross Profit	—	—	$0.00	$13.00K
Research & Development	$27.64M	$8.97M	$6.32M	$6.38M
Selling, General & Admin	$15.66M	$8.14M	$6.46M	$8.72M
Operating Expenses	$43.30M	$17.11M	$12.78M	$15.10M
Operating Income	-$40.60M	-$15.77M	-$12.78M	-$15.09M
EBITDA	-$37.61M	$7.32M	-$14.87M	$75.44M
Pretax Income	-$37.66M	$5.09M	-$15.92M	$75.32M
Income Tax	$100.00K	$0.00	$3.18M	$11.31M
Net Income	-$36.56M	$5.53M	-$19.06M	$64.05M
Diluted EPS	-0.94	0.14	-0.48	1.50
Diluted Shares	39.00M	40.57M	40.85M	42.42M

ORMP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$40.46M	$9.05M	$54.42M	$45.95M
Receivables	—	—	$0.00	$4.64M
Current Assets	$157.11M	$162.58M	$143.22M	$133.27M
Total Assets	$161.64M	$220.55M	$155.28M	$230.86M
Current Liabilities	$5.75M	$53.21M	$5.68M	$19.09M
Total Debt	$894.00K	$51.62M	$372.00K	$825.00K
Total Liabilities	$10.49M	$57.66M	$9.93M	$31.12M
Retained Earnings	-$163.08M	-$157.56M	-$176.62M	-$123.44M
Shareholders' Equity	$151.81M	$163.82M	$146.26M	$199.74M
Working Capital	$151.36M	$109.37M	$137.54M	$114.19M
Net Debt	—	$41.96M	—	—

ORMP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$27.92M	-$10.29M	-$8.41M	-$9.14M
Capital Expenditure	-$496.00K	-$254.00K	-$18.00K	-$1.93M
Free Cash Flow	-$28.41M	-$10.55M	-$8.43M	-$11.08M
Depreciation & Amortisation	$58.00K	$196.00K	$193.00K	$121.00K
Stock-Based Compensation	$11.51M	$4.21M	$4.05M	$5.99M
Investing Cash Flow	$30.21M	-$73.04M	$105.82M	$5.44M
Financing Cash Flow	$10.78M	$51.98M	-$52.04M	-$4.74M
Share Repurchases	—	$0.00	-$2.48M	-$4.74M
Net Change in Cash	$13.07M	-$31.36M	$45.37M	-$8.44M

ORMP Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$2.00M	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$1.99M	$0.00	$0.00	$0.00	$0.00
Gross Profit	$13.00K	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.21M	$1.03M	$1.15M	$1.99M	$1.59M
Selling, General & Admin	$2.31M	$1.46M	$1.27M	$3.68M	$2.06M
Operating Expenses	$4.51M	$2.49M	$2.43M	$5.67M	$3.66M
Operating Income	-$4.50M	-$2.49M	-$2.43M	-$5.67M	-$3.66M
EBITDA	-$4.47M	$13.16M	$59.48M	$9.83M	-$3.63M
Pretax Income	-$7.06M	$13.13M	$59.45M	$9.80M	$49.44M
Income Tax	$584.00K	-$126.00K	$11.06M	-$212.00K	$11.13M
Net Income	-$7.64M	$13.29M	$48.40M	$10.01M	$38.31M
Diluted EPS	-0.19	0.31	1.13	—	0.91
Diluted Shares	41.23M	42.61M	42.77M	—	41.97M

ORMP Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$74.52M	$15.80M	$52.18M	$45.95M	$13.20M
Receivables	—	—	—	$4.64M	$0.00
Current Assets	$131.48M	$99.03M	$136.12M	$133.27M	$68.15M
Total Assets	$147.54M	$161.68M	$220.49M	$230.86M	$268.85M
Current Liabilities	$5.49M	$3.69M	$6.12M	$19.09M	$10.56M
Total Debt	$301.00K	$912.00K	$860.00K	$825.00K	$761.00K
Total Liabilities	$7.64M	$8.10M	$18.16M	$31.12M	$30.57M
Retained Earnings	-$184.26M	-$170.97M	-$122.58M	-$123.44M	-$85.12M
Shareholders' Equity	$140.81M	$154.53M	$203.28M	$199.74M	$238.28M
Working Capital	$125.98M	$95.33M	$130.00M	$114.19M	$57.59M

ORMP Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.52M	-$3.54M	-$1.63M	-$466.00K	-$2.92M
Capital Expenditure	-$3.00K	-$4.00K	-$2.13M	—	-$5.00K
Free Cash Flow	-$3.52M	-$3.54M	-$3.75M	-$264.00K	-$2.92M
Depreciation & Amortisation	$30.00K	$30.00K	$31.00K	$30.00K	$30.00K
Stock-Based Compensation	$2.19M	$800.00K	$719.00K	$2.28M	$1.74M
Investing Cash Flow	$23.62M	-$54.85M	$38.36M	-$1.68M	-$19.49M
Financing Cash Flow	$0.00	-$371.00K	-$361.00K	-$4.01M	-$10.36M
Dividends Paid	$0.00	—	—	—	-$10.36M
Share Repurchases	—	—	-$361.00K	-$4.01M	—
Net Change in Cash	$20.10M	-$58.76M	$36.38M	-$6.16M	-$32.77M

Market Snapshot

About

Oramed Pharmaceuticals Inc. is an Israeli biotechnology company developing oral drug delivery systems, primarily focused on oral insulin and other oral formulations of injectable therapies for diabetes treatment.